What the company does
Adbiotech develops antibody-based biological products designed to prevent and treat diseases in livestock, aquaculture, and humans, offering alternatives to conventional vaccines and antibiotics.
Its products target farmers, aquaculture operators, and the broader animal-health supply chain. Listed on KOSDAQ, Korea's tech and small-cap board, the company's core platform is IgY technology, which extracts disease-fighting antibodies from egg yolk to create natural passive-immune preparations against viruses, bacteria, and parasites.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue · FY2025
US$9.3M
▲ +15.8% YoY
Operating profit · FY2025
−US$2.5M
Loss narrowed
Net income · FY2025
−US$2.4M
Loss narrowed
Revenue
- FY2023US$7.6M
- FY2024US$8.1M
- FY2025US$9.3M
Operating profit
- FY2023−US$3.5M
- FY2024−US$3M
- FY2025−US$2.5M
Net income
- FY2023−US$3.9M
- FY2024−US$6.5M
- FY2025−US$2.4M
Key ratios (FY2025)
ROE
-24.6%
Debt/Eq
257.5%
Op. margin
-27.1%
Net margin
-25.8%
Rev. YoY
▲ +15.8%
Price charts coming soon
Interactive price history isn't here yet. Would you use it?